GlassScriptPhysician profile
Gary S Hymes
NPI 1598765679
$4,616.73
in general payments reported to CMS, 2019-2025
25 companies · $544 in 2025
The $544 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $356 · 2021: $890 · 2022: $1,034 · 2023: $479 · 2024: $885 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,906.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $516.33 | 2019-2025 | Esprit |
| Paratek Pharmaceuticals, INC. | $350.56 | 2021-2025 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $329.53 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $264.65 | 2020-2022 | |
| Stryker Corporation | $254.25 | 2019-2021 | |
| Treace Medical Concepts, INC. | $251.30 | 2024-2025 | |
| Medtronic, INC. | $243.01 | 2024 | Intellis Adaptivestim |
| Averitas Pharma INC. | $234.86 | 2023-2024 | Qutenza |
| Biotissue Holdings INC. | $228.58 | 2021 | |
| Smith+Nephew, INC. | $220.77 | 2021-2022 | |
| Kerecis Limited | $164.27 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Paragon 28, INC. | $156.69 | 2021-2022 | |
| Globus Medical, INC. | $147.73 | 2025 | Senza |
| Progenacare Global, LLC | $136.62 | 2023 | |
| Wright Medical Technology, INC. | $117.94 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $117.45 | 2020 | |
| Amgen INC. | $116.80 | 2024 | Krystexxa |
| Horizon Therapeutics Plc | $116.06 | 2023 | Krystexxa |
| Misonix INC | $113.97 | 2021 | |
| Anika Therapeutics, INC. | $105.84 | 2022 | |
| Nevro Corp. | $104.16 | 2023 | Senza |
| Grt US Holding, INC. | $99.96 | 2022 | |
| Organogenesis INC. | $93.91 | 2022 | |
| Depuy Synthes Sales INC. | $84.82 | 2022 | |
| Next Science LLC | $46.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Hymes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.